Thomas Richard Kassberg

All filings by Thomas Richard Kassberg on record concern Ultragenyx Pharmaceutical Inc., in the capacity of senior executive. We count 36 filings; the first trade dates from 21 May 2016 and the latest from 1 March 2025.

On the market, this insider has only sold: 7 sales, €1.4M in total. Outside the open market, there are 27 share grants and 2 option exercises.

Most recently, on 4 March 2025, the filings show a share grant in Ultragenyx Pharmaceutical Inc. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.